Table 1:
Clinical characteristics of the neoadjuvant chemotherapy high grade serous ovarian cancer patient cohort
| Characteristics, n (%) | DNA-seq patients (32) | RNA-seq patients (20) |
|---|---|---|
| Median age at diagnosis, years (range) | 60 (43-86) | 61 (46-80) |
| Median cycles of neoadjuvant chemotherapy (range) | 3 (3-6) | 3 (3-4) |
| FIGO stage | ||
| IIIC | 21 (66%) | 16 (80%) |
| IVA | 2 (6%) | 0 |
| IVB | 9 (28%) | 4 (20%) |
| Primary disease site | ||
| Ovary | 17 (53%) | 12 (60%) |
| Fallopian tube | 15 (47%) | 8 (40%) |
| Peritoneum | 0 | 0 |
| Tumor debulking status | ||
| optimal | 26 (81%) | 16 (80%) |
| suboptimal | 6 (19%) | 4 (20%) |
| Chemotherapy response score * | ||
| 1 | 15 (48%) | 8 (42%) |
| 2 | 8 (26%) | 7 (37%) |
| 3 | 8 (26%) | 4 (21%) |
| Primary platinum response | ||
| Sensitive | 18 (56%) | 12 (60%) |
| Resistant | 14 (44%) | 8 (40%) |
| Median Progression free survival, days (range) | 460 (246-1693) | 521 (199-1257) |
| Median overall survival, days (range) | 734 (292-2248) | 720 (292-2248) |
*
1 patient with unknown score